1st Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$425,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Proposals to repeal LIFO

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Incentives for health information technology, Affordable Care Act implementation, and other healthcare policy issues. Proposed regulation of medical software. H.R. 3303 "SOFTWARE Act of 2013". S. 2007 "PROTECT Act of 2014".

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 2007 (113th), H.R. 3303 (113th)

Veterans VET

Existing Department of Veterans' Affairs Pharmaceutical Prime Vendor contract.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H.R. 1416 " Cancer Patient Protection Act of 2013" H.R. 4302 "Protecting Access to Medicare Act of 2014"Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93. S.806/H.R. 800 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —
MATT BROW —
KEAGAN R LENIHAN —
GEOFF WERTH —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 2869 (113th), H.R. 1416 (113th), H.R. 4302 (113th), S. 806 (113th), H.R. 800 (113th)

Pharmacy PHA

Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.